Journal article
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
JF Seymour, S Ma, DM Brander, MY Choi, J Barrientos, MS Davids, MA Anderson, AW Beaven, ST Rosen, CS Tam, B Prine, SK Agarwal, W Munasinghe, M Zhu, LL Lash, M Desai, E Cerri, M Verdugo, SY Kim, RA Humerickhouse Show all
Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2017
Abstract
Background Selective BCL2 inhibition with venetoclax has substantial activity in patients with relapsed or refractory chronic lymphocytic leukaemia. Combination therapy with rituximab enhanced activity in preclinical models. The aim of this study was to assess the safety, pharmacokinetics, and activity of venetoclax in combination with rituximab. Methods Adult patients with relapsed or refractory chronic lymphocytic leukaemia (according to the 2008 Modified International Workshop on CLL guidelines) or small lymphocytic lymphoma were eligible for this phase 1b, dose-escalation trial. The primary outcomes were to assess the safety profile, to determine the maximum tolerated dose, and to establ..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
AbbVie Inc and Genentech Inc.